International Journal for Parasitology: Drugs and Drug Resistance最新文献

{"title":"Robenidine derivatives as potential antischistosomal drug candidates","authors":"Christian N. Lotz ,&nbsp;Alina Krollenbrock ,&nbsp;Lea Imhof ,&nbsp;Michael Riscoe ,&nbsp;Jennifer Keiser","doi":"10.1016/j.ijpddr.2024.100546","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100546","url":null,"abstract":"<div><p>Schistosomiasis caused by <em>Schistosoma</em> spp. is a disease that causes a considerable health burden to millions of people worldwide. The limited availability of effective drugs on the market and the increased risk of resistance development due to extensive usage, highlight the urgent need for new antischistosomal drugs. Recent studies have shown that robenidine derivatives, containing an aminoguanidine core, exhibit promising activities against <em>Plasmodium falciparum</em>, motivating further investigation into their efficacy against <em>Schistosoma mansoni,</em> due to their similar habitat and the resulting related cellular mechanisms like the heme detoxification pathway. The conducted phenotypic screening of robenidine and 80 derivatives against newly transformed schistosomula and adult <em>Schistosoma mansoni</em> yielded 11 candidates with low EC₅₀ values for newly transformed schistosomula (1.12–4.63 μM) and adults (2.78–9.47 μM). The structure-activity relationship revealed that electron-withdrawing groups at the phenyl moiety, as well as the presence of methyl groups adjacent to the guanidine moiety, enhanced the activity of derivatives against both stages of <em>Schistosoma mansoni</em>. The two compounds <em>2,2′-Bis[(3-cyano-4-fluorophenyl)methylene] carbonimidic Dihydrazide Hydrochloride</em> (<strong>1</strong>) and <em>2,2′-Bis[(4-difluoromethoxyphenyl) ethylidene] carbonimidic Dihydrazide Hydrochloride</em> (<strong>19</strong>), were selected for an in vivo study in <em>Schistosoma mansoni</em>-infected mice based on their potency, cytotoxicity, pharmacokinetic-, and physicochemical properties, but failed to reduce the worm burden significantly (worm burden reduction &lt;20%). Thus, robenidine derivatives require further refinements to obtain higher antischistosomal specificity and in vivo activity.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000277/pdfft?md5=07fc6d729d2617e9566802c376d81c41&pid=1-s2.0-S2211320724000277-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140906878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faecal egg count reduction tests and nemabiome analysis reveal high frequency of multi-resistant parasites on sheep farms in north-east Germany involving multiple strongyle parasite species","authors":"Jürgen Krücken ,&nbsp;Paula Ehnert ,&nbsp;Stefan Fiedler ,&nbsp;Fabian Horn ,&nbsp;Christina S. Helm ,&nbsp;Sabrina Ramünke ,&nbsp;Tanja Bartmann ,&nbsp;Alexandra Kahl ,&nbsp;Ann Neubert ,&nbsp;Wiebke Weiher ,&nbsp;Ricarda Daher ,&nbsp;Werner Terhalle ,&nbsp;Alexandra Klabunde-Negatsch ,&nbsp;Stephan Steuber ,&nbsp;Georg von Samson-Himmelstjerna","doi":"10.1016/j.ijpddr.2024.100547","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100547","url":null,"abstract":"<div><p>Anthelmintic resistance in sheep parasitic gastrointestinal nematodes is widespread and a severe health and economic issue but prevalence of resistance and involved parasite species are unknown in Germany. Here, the faecal egg count reduction test (FECRT) was performed on eight farms using fenbendazole, ivermectin and moxidectin and on four farms using only moxidectin. A questionnaire was used to obtain data on management practices to potentially identify risk factors for presence of resistance. All requirements of the recently revised WAAVP guideline for diagnosing anthelmintic resistance using the FECRT were applied. Nematode species composition in pre- and post-treatment samples was analysed with the nemabiome approach. Using the eggCounts statistic package, resistance against fenbendazole, ivermectin and moxidectin was found on 7/8, 8/8 and 8/12 farms, respectively. No formal risk factor analysis was conducted since resistance was present on most farms. Comparison with the bayescount R package results revealed substantial agreement between methods (Cohen's κ = 0.774). In contrast, interpretation of data comparing revised and original WAAVP guidelines resulted in moderate agreement (Cohen's κ = 0.444). The FECR for moxidectin was significantly higher than for ivermectin and fenbendazole. Nemabiome data identified 4 to 12 species in pre-treatment samples and treatments caused a small but significant decrease in species diversity (inverse Simpson index). Non-metric multidimensional scaling and k-means clustering were used to identify common patterns in pre- and post-treatment samples. However, post-treatment samples were scattered among the pre-treatment samples. Resistant parasite species differed between farms. In conclusion, the revised FECRT guideline allows robust detection of anthelmintic resistance. Resistance was widespread and involved multiple parasite species. Resistance against both drug classes on the same farm was common. Further studies including additional drugs (levamisole, monepantel, closantel) should combine sensitive FECRTs with nemabiome data to comprehensively characterise the anthelmintic susceptibility status of sheep nematodes in Germany.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000289/pdfft?md5=cefc4dcf8db5b07c8c628daa3b7cf9c9&pid=1-s2.0-S2211320724000289-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro and in vivo activities of a trithiolato-diRuthenium complex conjugated with sulfadoxine against the apicomplexan parasite Toxoplasma gondii","authors":"Ghalia Boubaker ,&nbsp;Alice Bernal ,&nbsp;Anitha Vigneswaran ,&nbsp;Dennis Imhof ,&nbsp;Maria Cristina Ferreira de Sousa ,&nbsp;Kai Pascal Alexander Hänggeli ,&nbsp;Noé Haudenschild ,&nbsp;Julien Furrer ,&nbsp;Emilia Păunescu ,&nbsp;Oksana Desiatkina ,&nbsp;Andrew Hemphill","doi":"10.1016/j.ijpddr.2024.100544","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100544","url":null,"abstract":"<div><p>Organometallic compounds, including Ruthenium complexes, have been widely developed as anti-cancer chemotherapeutics, but have also attracted much interest as potential anti-parasitic drugs. Recently hybrid drugs composed of organometallic Ruthenium moieties that were complexed to different antimicrobial agents were synthesized. One of these compounds, a trithiolato-diRuthenium complex (RU) conjugated to sulfadoxine (SDX), inhibited proliferation of <em>Toxoplasma gondii</em> tachyzoites grown in human foreskin fibroblast (HFF) monolayers with an IC₅₀ &lt; 150 nM, while SDX and the non-modified RU complex applied either individually or as an equimolar mixture were much less potent. In addition, conjugation of SDX to RU lead to decreased HFF cytotoxicity. RU-SDX did not impair the <em>in vitro</em> proliferation of murine splenocytes at concentrations ranging from 0.1 to 0.5 μM but had an impact at 2 μM, and induced zebrafish embryotoxicity at 20 μM, but not at 2 or 0.2 μM. RU-SDX acted parasitostatic but not parasiticidal, and induced transient ultrastructural changes in the mitochondrial matrix of tachyzoites early during treatment. While other compounds that target the mitochondrion such as the uncouplers FCCP and CCCP and another trithiolato-Ruthenium complex conjugated to adenine affected the mitochondrial membrane potential, no such effect was detected for RU-SDX. Evaluation of the <em>in vivo</em> efficacy of RU-SDX in a murine <em>T. gondii</em> oocyst infection model comprised of non-pregnant outbred CD1 mice showed no effects on the cerebral parasite burden, but reduced parasite load in the eyes and in heart tissue.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000253/pdfft?md5=1758646700d4ce7a5e7b5857d8207d26&pid=1-s2.0-S2211320724000253-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140825399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmodium RNA triphosphatase validation as antimalarial target","authors":"Sonia Moliner-Cubel ,&nbsp;Noemi Bahamontes-Rosa ,&nbsp;Ane Rodriguez-Alejandre ,&nbsp;Pamela M. Nassau ,&nbsp;Argyrides Argyrou ,&nbsp;Anshu Bhardwaja ,&nbsp;Rachel C. Buxton ,&nbsp;David Calvo-Vicente ,&nbsp;Bernadette Mouzon ,&nbsp;William McDowell ,&nbsp;Alfonso Mendoza-Losana ,&nbsp;Maria G. Gomez-Lorenzo","doi":"10.1016/j.ijpddr.2024.100537","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100537","url":null,"abstract":"<div><p>Target-based approaches have traditionally been used in the search for new anti-infective molecules. Target selection process, a critical step in Drug Discovery, identifies targets that are essential to establish or maintain the infection, tractable to be susceptible for inhibition, selective towards their human ortholog and amenable for large scale purification and high throughput screening. The work presented herein validates the <em>Plasmodium falciparum</em> mRNA 5’ triphosphatase (PfPRT1), the first enzymatic step to cap parasite nuclear mRNAs, as a candidate target for the development of new antimalarial compounds. mRNA capping is essential to maintain the integrity and stability of the messengers, allowing their translation. PfPRT1 has been identified as a member of the tunnel, metal dependent mRNA 5′ triphosphatase family which differs structurally and mechanistically from human metal independent mRNA 5′ triphosphatase. In the present study the essentiality of PfPRT1 was confirmed and molecular biology tools and methods for target purification, enzymatic assessment and target engagement were developed, with the goal of running a future high throughput screening to discover PfPRT1 inhibitors.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000186/pdfft?md5=e5fae98317910cf914e2a408c67afefe&pid=1-s2.0-S2211320724000186-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141163643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nourseothricin as a novel drug for selection of transgenic Giardia lamblia","authors":"Corina D. Wirdnam ,&nbsp;Dawid Warmus ,&nbsp;Carmen Faso","doi":"10.1016/j.ijpddr.2024.100543","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100543","url":null,"abstract":"<div><p>Functional gene and protein characterizations in parasitic protists are often limited by their genetic tractability. Despite the development of CRISPR-Cas9-derived or inspired approaches for a handful of protist parasites, the overall genetic tractability of these organisms remains limited. The intestinal parasite <em>Giardia lamblia</em> is one such species, with the added challenge of a paucity of reliable selection markers.</p><p>To address this limitation, we tested the feasibility of using Nourseothricin as an effective selection agent in Giardia. Here, we report that axenically-grown WB <em>Giardia</em> cells are sensitive to Nourseothricin and that engineering expression of the streptothricin acetyltransferase (SAT-1) gene from <em>Streptomyces rochei</em> in transgenic parasites confers resistance to this antibiotic. Furthermore, we determine that SAT-1-expressing parasites are cross-resistant neither to Neomycin nor Puromycin, which are widely used to select for transgenic parasites. Consequently, we show that Nourseothricin can be used in sequential combination with both Neomycin and Puromycin to select for dual transfection events.</p><p>This work increases the number of reliable selection agents and markers for <em>Giardia</em> genetic manipulation, expanding the limited molecular toolbox for this species of global medical importance.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000241/pdfft?md5=a08affe1983c77d439da5cd975827679&pid=1-s2.0-S2211320724000241-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140807091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating cryptosporidiosis: A review on drug discovery strategies","authors":"Anne-Charlotte Lenière,&nbsp;Alexis Vlandas,&nbsp;Jérôme Follet","doi":"10.1016/j.ijpddr.2024.100542","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100542","url":null,"abstract":"<div><p>Despite several decades of research on therapeutics, cryptosporidiosis remains a major concern for human and animal health. Even though this field of research to assess antiparasitic drug activity is highly active and competitive, only one molecule is authorized to be used in humans. However, this molecule was not efficacious in immunocompromised people and the lack of animal therapeutics remains a cause of concern. Indeed, the therapeutic arsenal needs to be developed for both humans and animals. Our work aims to clarify research strategies that historically were diffuse and poorly directed. This paper reviews <em>in vitro</em> and <em>in vivo</em> methodologies to assess the activity of future therapeutic compounds by screening drug libraries or through drug repurposing. It focuses on High Throughput Screening methodologies (HTS) and discusses the lack of knowledge of target mechanisms. In addition, an overview of several specific metabolic pathways and enzymatic activities used as targets against <em>Cryptosporidium</em> is provided. These metabolic processes include glycolytic pathways, fatty acid production, kinase activities, tRNA elaboration, nucleotide synthesis, gene expression and mRNA maturation. As a conclusion, we highlight emerging future strategies for screening natural compounds and assessing drug resistance issues.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221132072400023X/pdfft?md5=2c999fcac43efe99f255fbf85f5d4e5d&pid=1-s2.0-S221132072400023X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140645476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the antiplasmodial efficacy of synthetic 2,5-diphenyloxazole analogs of compounds naturally derived from Oxytropis lanata","authors":"Nanang R. Ariefta ,&nbsp;Koichi Narita ,&nbsp;Toshihiro Murata ,&nbsp;Yoshifumi Nishikawa","doi":"10.1016/j.ijpddr.2024.100540","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100540","url":null,"abstract":"<div><p>The persistent prevalence and dissemination of drug-resistant malaria parasites continue to challenge the progress of malaria eradication efforts. As a result, there is an urgent need to search for and develop innovative therapies. In this study, we screened synthetic 2,5-diphenyloxazole analogs from <em>Oxytropis lanata</em>. Among 48 compounds, 14 potently inhibited the proliferation of <em>P. falciparum</em> strains 3D7 (chloroquine-sensitive) and K1 (multidrug-resistant) in vitro, exhibited IC₅₀ values from 3.38 to 12.65 μM and 1.27–6.19 μM, respectively, and were toxic to human foreskin fibroblasts at 39.53–336.35 μM. Notably, Compounds <strong>31</strong> (2-(2′,3′-dimethoxyphenyl)-5-(2″-hydroxyphenyl)oxazole) and <strong>32</strong> (2-(2′,3′-dimethoxyphenyl)-5-(2″-benzyloxyphenyl)oxazole) exhibited the highest selectivity indices (SIs) against both <em>P. falciparum</em> strains (3D7/K1), with values &gt; 40.20/&gt;126.58 and &gt; 41.27/&gt; 59.06, respectively. In the IC₅₀ speed and stage-specific assays, Compounds <strong>31</strong> and <strong>32</strong> showed slow action, along with distinct effects on the ring and trophozoite stages. Microscopy observations further revealed that both compounds impact the development and delay the progression of the trophozoite and schizont stages in <em>P. falciparum</em> 3D7, especially at concentrations 100 times their IC₅₀ values. In a 72-h in vitro exposure experiment at their respective IC₈₀ in <em>P. falciparum</em> 3D7, significant alterations in parasitemia levels were observed compared to the untreated group. In Compound <strong>31</strong>-treated cultures, parasites shrank and were unable to reinvade red blood cells (RBCs) during an extended 144-h incubation period, even after compound removal from the culture. In vivo assessments were conducted on <em>P. yoelii</em> 17XNL-infected mice treated with Compounds <strong>31</strong> and <strong>32</strong> at 20 mg/kg administered once daily for ten days. The treated groups showed statistically significant lower peaks of parasitemia (Compound <strong>31</strong>-treated: trial 1 12.7%, trial 2 15.8%; Compound <strong>32</strong>-treated: trial 1 12.7%, trial 2 14.0%) compared to the untreated group (trial 1 21.7%, trial 2 28.3%). These results emphasize the potential of further developing 2,5-diphenyloxazoles as promising antimalarial agents.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000216/pdfft?md5=1dfb0cb947387ac4f75ca834b9284ec5&pid=1-s2.0-S2211320724000216-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-throughput prioritization of target proteins for development of new antileishmanial compounds","authors":"Lucas G. Azevedo ,&nbsp;Ezequiel Sosa ,&nbsp;Artur T.L. de Queiroz ,&nbsp;Aldina Barral ,&nbsp;Richard J. Wheeler ,&nbsp;Marisa F. Nicolás ,&nbsp;Leonardo P. Farias ,&nbsp;Dario Fernández Do Porto ,&nbsp;Pablo Ivan P. Ramos","doi":"10.1016/j.ijpddr.2024.100538","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100538","url":null,"abstract":"<div><p>Leishmaniasis, a vector-borne disease, is caused by the infection of <em>Leishmania</em> spp., obligate intracellular protozoan parasites. Presently, human vaccines are unavailable, and the primary treatment relies heavily on systemic drugs, often presenting with suboptimal formulations and substantial toxicity, making new drugs a high priority for LMIC countries burdened by the disease, but a low priority in the agenda of most pharmaceutical companies due to unattractive profit margins. New ways to accelerate the discovery of new, or the repositioning of existing drugs, are needed. To address this challenge, our study aimed to identify potential protein targets shared among clinically-relevant <em>Leishmania</em> species. We employed a subtractive proteomics and comparative genomics approach, integrating high-throughput multi-omics data to classify these targets based on different druggability metrics. This effort resulted in the ranking of 6502 ortholog groups of protein targets across 14 pathogenic <em>Leishmania</em> species. Among the top 20 highly ranked groups, metabolic processes known to be attractive drug targets, including the ubiquitination pathway, aminoacyl-tRNA synthetases, and purine synthesis, were rediscovered. Additionally, we unveiled novel promising targets such as the nicotinate phosphoribosyltransferase enzyme and dihydrolipoamide succinyltransferases. These groups exhibited appealing druggability features, including less than 40% sequence identity to the human host proteome, predicted essentiality, structural classification as highly druggable or druggable, and expression levels above the 50th percentile in the amastigote form. The resources presented in this work also represent a comprehensive collection of integrated data regarding trypanosomatid biology.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000198/pdfft?md5=fb65abd832eb2668709c9d19b5045eda&pid=1-s2.0-S2211320724000198-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140644215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral administration of IPI549 protects mice from neuropathology and an overwhelming inflammatory response during experimental cerebral malaria","authors":"Zhuoru Jin ,&nbsp;Wei Pang ,&nbsp;Yan Zhao ,&nbsp;Hui Min ,&nbsp;Shijie Yao ,&nbsp;Zhifang Bian ,&nbsp;Yixin Wen ,&nbsp;Chuanyang Peng ,&nbsp;Yaming Cao ,&nbsp;Li Zheng","doi":"10.1016/j.ijpddr.2024.100539","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100539","url":null,"abstract":"<div><p>Infection with <em>Plasmodium falciparum</em> is often deadly when it results in cerebral malaria, which is associated with neuropathology described as an overwhelming inflammatory response and mechanical obstruction of cerebral microvascular. PI3Kγ is a critical component of intracellular signal transduction and plays a central role in regulating cell chemotaxis, migration, and activation. The purpose of this study was to examine the relationship between inhibiting the PI3Kγ pathway and the outcome of experimental cerebral malaria (ECM) in C57BL/6J mice infected with the mouse malaria parasite, <em>Plasmodium berghei</em> ANKA. We observed that oral administration of the PI3Kγ inhibitor IPI549 after infection completely protected mice from ECM. IPI549 treatment significantly dampened the magnitude of inflammatory responses, with reduced production of pro-inflammatory factors, decreased T cell activation, and altered differentiation of antigen-presenting cells. IPI549 treatment protected the infected mice from neuropathology, as assessed by an observed reduction of pathogenic T cells in the brain. Treating the infected mice with IPI549 three days after parasite inoculation improved the murine blood brain barrier (BBB) integrity and helped the mice pass the onset of ECM. Together, these data indicate that oral administration of the PI3Kγ inhibitor IPI549 has a suppressive role in host inflammation and alleviates cerebral pathology, which supports IPI549 as a new malaria treatment option with potential therapeutic implications for cerebral malaria.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000204/pdfft?md5=01acea5ceacbc6298fc27269173191f8&pid=1-s2.0-S2211320724000204-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of antiplasmodial pyridine carboxamides and thiocarboxamides","authors":"Alexa Redway ,&nbsp;Christina Spry ,&nbsp;Ainka Brown ,&nbsp;Ursula Wiedemann ,&nbsp;Imam Fathoni ,&nbsp;Larnelle F. Garnie ,&nbsp;Deyun Qiu ,&nbsp;Timothy J. Egan ,&nbsp;Adele M. Lehane ,&nbsp;Yvette Jackson ,&nbsp;Kevin J. Saliba ,&nbsp;Nadale Downer-Riley","doi":"10.1016/j.ijpddr.2024.100536","DOIUrl":"https://doi.org/10.1016/j.ijpddr.2024.100536","url":null,"abstract":"<div><p>Malaria continues to be a significant burden, particularly in Africa, which accounts for 95% of malaria deaths worldwide. Despite advances in malaria treatments, malaria eradication is hampered by insecticide and antimalarial drug resistance. Consequently, the need to discover new antimalarial lead compounds remains urgent. To help address this need, we evaluated the antiplasmodial activity of twenty-two amides and thioamides with pyridine cores and their non-pyridine analogues. Twelve of these compounds showed <em>in vitro</em> anti-proliferative activity against the intraerythrocytic stage of <em>Plasmodium falciparum</em>, the most virulent species of <em>Plasmodium</em> infecting humans. Thiopicolinamide <strong>13i</strong> was found to possess submicromolar activity (IC₅₀ = 142 nM) and was &gt;88-fold less active against a human cell line. The compound was equally effective against chloroquine-sensitive and -resistant parasites and did not inhibit β-hematin formation, pH regulation or <em>Pf</em>ATP4. Compound <strong>13i</strong> may therefore possess a novel mechanism of action.</p></div>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211320724000174/pdfft?md5=764fef1dfcf7fb9e855badc572300146&pid=1-s2.0-S2211320724000174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140644250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}